Latest News and Press Releases

Autolus announces the publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025.

Autolus announced its operational and financial results for the second quarter ended June 30, 2025.

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 E

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory

Autolus announces recent updates and financial results for the full year ended December 31, 2024.

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with obe-cel with a median follow-up of 20.3 monthsLow incidence of immune-related toxicity:...

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024